Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc demonstrates a positive outlook due to projected growth in its PSMA PET imaging revenue, with estimates indicating an increase from a low to mid-single digit market share to a high-single digit share by 1Q25. The introduction of a new Pylarify formulary is expected to enhance production capabilities and contribute to growth in Pylarify revenues beginning in 4Q26, bolstered by eligibility for three years of unique production through TPT. Additionally, there is a strong potential for increased earnings per share in 2026-2027 if Lantheus's non-Pylarify segments outperform expectations and provide a substantial contribution to revenue growth and margins.

Bears say

Lantheus Holdings Inc is facing a negative outlook primarily due to a decline in its revenue from Pylarify, which reported $260 million, a decrease of 8% year-over-year and falling short of expectations by approximately $14 million. Additionally, unit growth was lower than anticipated, registering only a 2% increase year-over-year and experiencing a significant price headwind of 10% during the quarter. These factors contribute to a reduced growth profile for Lantheus relative to its profitable SMID MedTech peers, with revised forecasts for 2025-2026 suggesting further challenges ahead.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Jan 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.